サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1772254

米国の分子生物学用酵素・試薬・キット市場：市場規模・シェア・動向分析 (製品別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2033年)

U.S. Molecular Biology Enzymes, Reagents And Kits Market Size, Share & Trends Analysis Report By Product (Kit and Reagents, Enzymes), By Application (Cloning, NGS, PCR), By End Use, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 137 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
米国の分子生物学用酵素・試薬・キット市場：市場規模・シェア・動向分析 (製品別・用途別・最終用途別・地域別)、セグメント別予測 (2025年～2033年)
出版日: 2025年06月30日
発行: Grand View Research
ページ情報: 英文 137 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向：

米国の分子生物学用酵素・試薬・キットの市場規模は2024年に59億5,000万米ドルと推計され、2025年から2033年にかけてCAGR 9.65%で成長すると予測されています。

米国疾病予防管理センター（CDC）によると、クラミジア、淋病、梅毒などの性病は過去10年間で着実に増加しており、近年では250万件以上の症例が報告されています。研究、診断、治療における分子技術の応用の拡大。

米国がん協会によると、2024年には、泌尿器膀胱の症例を除き、基底細胞および扁平上皮の皮膚がんと非浸潤性がんin situを除く、200万人以上の新規がん症例が米国で診断されると予測されています。このような疾病負担の増加は、同市場における同国のリーダーシップを維持すると予想されます。

2024年11月、カリフォルニア州公衆衛生局（CDPH）は、米国初のクレードi型mpoxの症例を臨床検査で確認しました。診断が下されたのは、流行地域に最近渡航した患者でした。PCR検査により非バリオラオルソポックスウイルスが同定され、クレードI型mpoxが確認されました。クレードI mpoxの出現は、迅速かつ正確な分子診断の必要性を強調し、次世代PCRおよびシークエンス技術への投資を促進しています。

この市場には、PCR、qPCR、RT-PCR、クローニング、シークエンシング、遺伝子発現解析などのプロセス用に設計されたポリメラーゼ、リガーゼ、ヌクレアーゼ、バッファー、特殊試薬キットなど、幅広い製品が含まれます。さらに、エンテロウイルスは5歳未満の幼児にも感染し、感染した幼児の約41％が酸素吸入を必要としています。さらに、2021年5月に米国国立医学図書館が発表した論文によると、米国では毎年人口の約40％がピロリ菌感染の影響を受けています。

承認や資金提供という形での政府支援の存在は、予測期間中の市場成長を促進すると予想されます。例えば、2022年5月、アボット社は米国FDAからAlinity m STI Assayの承認を取得しました。この検査はSTIの鑑別・検出が可能です。さらに2020年には、ASPRのBiomedical Advanced Research and Development AuthorityとNIHのNational Institute of Allergy and Infectious DiseasesがAntimicrobial Resistance Diagnostic Challengeを開催し、Visby Medicalの迅速PCR検査が1,900万米ドルの連邦資金を獲得しました。

さらに2022年9月、レッドバッド・メディシンはシリーズAで1,000万米ドルの資金を調達しました。連邦政府からの資金援助は、地方や州の検査機関の能力向上にも役立ち、需要の増加に対応できるようになります。同様に、2023年6月、アクセラレート・ダイアグノスティックス社は、Waveプラットフォームと新規迅速検査の開発を加速させるため、2,400万米ドルを受領しました。感染症の多様性と原因物質の耐性化のため、感染症の分子診断検査メニューは固定的・表面的なものでは許されないです。

さらに、プロメガ・コーポレーションやサーモ・フィッシャー・サイエンティフィックなど、コスト効率が高く、高品質で、診断に使用する酵素を幅広く提供する主要企業が米国に進出していることも、米国市場を牽引しています。これらの企業は、バイオセンサー、糖尿病測定器、ポイントオブケア機器、肝臓、心臓血管、腎臓、その他の疾患の体外診断に使用できる酵素を提供しています。プロメガ社は2024年9月、法医学DNA分析における吃音をカットする新しい酵素の変種を発表し、ポリメラーゼキットの革新性を強調しました。一方、qPCRとRT-PCRキットは、PCRシステムのアップグレードとハイスループットラボの導入に支えられ、好調を維持しています。さらに、2021年2月には、アジレント・テクノロジーがAgilent Dako SARS-CoV-2 IgG酵素結合免疫吸着測定キットを発売しました。このキットは、ヒトの血清または血漿中のSARS-CoV-2に対するIgG抗体を検出します。

診断アッセイに使用される主な試薬には、蛍光タグ、洗浄バッファー、特異抗体、免疫化学検査用のタンパク質バイオマーカー、PCR検査用のdNTPやプライマーミックスなどの必須化学物質が含まれます。分子診断では、蛍光標識ヌクレオチドやプライマーが、特にアボット社、イルミナ社、ロシュ・ダイアグノスティックス社などの業界大手によって頻繁に利用されています。

COVID-19関連試薬に対する規制当局の承認も市場を活性化しています。米国FDAは2021年3月にBioFire Respiratory Panel 2.1を510（k）認可し、COVID-19を含む複数の呼吸器感染症の検出を可能にしました。同様に、2020年4月、Ortho Clinical Diagnosticsは、VITROS診断システム上で動作するVITROS Immunodiagnostic Anti-SARS-CoV-2 Total Reagent Pack and Calibratorsの緊急使用許可（EUA）を取得しました。このような承認により、パンデミックの初期に発生した一時的な供給不足の中でも、ヘルスケア専門家はCOVID-19をより適切に管理し、予防することができます。これらの供給不足は、政府の介入、サプライチェーンの復旧、代替製品の発売により、最終的には緩和されました。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 分子生物学用酵素・試薬・キット市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 分子生物学用酵素・試薬・キット市場：分析ツール
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 分子生物学用酵素・試薬・キット市場：製品別の推定・動向分析

  • 市場シェア：製品別（2024年・2033年）
  • セグメントダッシュボード
  • 世界の分子生物学用酵素・試薬・キット市場の展望：製品別
  • 市場規模の予測と動向分析（2021年～2033年）
    • キット・試薬
    • 酵素

第5章 分子生物学用酵素・試薬・キット市場：用途別の推定・動向分析

  • 市場シェア：用途別（2024年・2033年）
  • セグメントダッシュボード
  • 世界の分子生物学用酵素・試薬・キット市場の展望：用途別
  • 市場規模の予測と動向分析（2021年～2033年）
    • クローン
    • シーケンシング
    • PCR
    • エピジェネティクス
    • 遺伝子型判定
    • RCA/MDA
    • RNAセラピューティクス
    • トランスクリプトミクス
    • プロテオミクス
    • 液体生検
    • その他の用途

第6章 分子生物学用酵素・試薬・キット市場：最終用途別の推定・動向分析

  • 市場シェア：最終用途別（2024年・2033年）
  • セグメントダッシュボード
  • 世界の分子生物学用酵素・試薬・キット市場の展望：最終用途別
  • 市場規模の予測と動向分析（2021年～2033年）
    • 製薬・バイオテクノロジー
    • 学術研究
    • 病院・診断
    • その他

第7章 競合情勢

  • 最新動向と影響分析：主な市場参入企業別
  • 企業分類
  • 企業ヒートマップ分析
  • 企業プロファイル
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Promega Corporation
    • New England Biolabs
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd.
    • Bio-Rad Laboratories, Inc.
    • Takara Bio, Inc.
    • LGC Limited
図表

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 U.S. Molecular biology enzymes, reagents and kits Market, By Product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Molecular biology enzymes, reagents and kits Market, By Application, 2021 - 2033 (USD Million)
  • Table 5 U.S. Molecular biology enzymes, reagents and kits Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research
  • Fig. 4 Value-chain-based sizing & forecasting
  • Fig. 5 QFD modelling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Market outlook
  • Fig. 9 Segment snapshot-1
  • Fig. 10 Segment snapshot-2
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Market trends & outlook
  • Fig. 13 Porter's five force analysis
  • Fig. 14 PESTEL analysis
  • Fig. 15 U.S. molecular biology enzymes, reagents and kits market: Product outlook key takeaways
  • Fig. 16 U.S. molecular biology enzymes, reagents and kits market: Product movement analysis
  • Fig. 17 Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 PCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 qPCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 RT-PCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Library Preparation Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Cloning Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Purification Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Gene Editing Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Other Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 High Fidelity DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Pfu DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Phusion DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Hot Start DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Taq DNA Polymerases High Fidelity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Thermostable DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Standard Taq DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Tth DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Strand-displacing DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Bst DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Phi29 DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 RNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 T7 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 SP6 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 T3 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Other RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Reverse Transcriptase (RTs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 M-MLV RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 AMV RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Thermostable RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 DNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 T4 DNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 E. coli DNA Ligase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Taq DNA Ligase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 RNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Nucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 DNase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 RNase A, RNase H Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Nickases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Restriction Nucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 TdTs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Endonucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 EndoQ Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 AP Nuclease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Kinases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Phosphatases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 CRISPR-associated Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Cas9 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Cas12a (Cpf1) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Cas13 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Specialty Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 U.S. molecular biology enzymes, reagents and kits market: Application outlook key takeaways
  • Fig. 77 U.S. molecular biology enzymes, reagents and kits market: Application movement analysis
  • Fig. 78 Cloning - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Sequencing - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 PCR - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Epigenetics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Genotyping - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 RCA/MDA - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 RNA Therapeutics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Transcriptomics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Proteomics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Liquid Biopsy - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Other Applications - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 U.S. molecular biology enzymes, reagents and kits market: End Use outlook key takeaways
  • Fig. 90 U.S. molecular biology enzymes, reagents and kits market: End Use movement analysis
  • Fig. 91 Pharma & Biotech - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Academic & Research - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 93 Hospital & Diagnostics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Others - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
目次
Product Code: GVR-4-68040-645-5

Market Size & Trends:

The U.S. molecular biology enzymes, reagents and kits market size was estimated at USD 5.95 billion in 2024 and is projected to grow at a CAGR of 9.65% from 2025 to 2033. The market is driven by growing burden of chronic diseases and infectious diseases such as sexually transmitted diseases (STDs) across the U.S. According to the Centers for Disease Control and Prevention (CDC), STDs such as chlamydia, gonorrhea, and syphilis have been increasing steadily over the past decade, with over 2.5 million cases reported in recent years. The expanding application of molecular technologies in research, diagnostics, and therapeutics.

According to the American Cancer Society, over 2 million new cancer cases are projected to be diagnosed in the U.S. in 2024, excluding basal and squamous cell skin cancers and noninvasive carcinoma in situ, except for urinary bladder cases. This rising disease burden is expected to sustain the country's leadership in the market.

In November 2024, the California Department of Public Health (CDPH) confirmed the first case of clade I mpox in the U.S. through laboratory testing. The diagnosis was made in a patient who had recently traveled to an outbreak region. PCR testing identified non-variola orthopoxvirus and confirmed clade I mpox, with further analysis conducted by the CDC. The emergence of clade I mpox underscores the necessity for rapid and precise molecular diagnostics, fostering investment in next-generation PCR and sequencing technologies.

This market encompasses a broad range of products, including polymerases, ligases, nucleases, buffers, and specialized reagent kits designed for processes such as PCR, qPCR, RT-PCR, cloning, sequencing, and gene expression analysis. Furthermore, enterovirus also majorly affects the population with ages less than 5 years, of which around 41% of the infected toddlers require supplemental oxygen. In addition, according to the article published by the National Library of Medicine in May 2021, around 40 % of the U.S. population in the U.S. is affected by H. pylori infection every year.

The presence of government support in the form of approvals and funding is anticipated to fuel the market growth over the forecast period. For instance, in May 2022, Abbot received approval for its Alinity m STI Assay from the U.S. FDA. The test is capable of differentiating and detecting STIs. In addition, in 2020, ASPR's Biomedical Advanced Research and Development Authority and NIH's National Institute of Allergy and Infectious Diseases organized the Antimicrobial Resistance Diagnostic Challenge in which Visby Medical's rapid PCR test won USD 19 million in federal funding.

In addition, in September 2022, Redbud Medicine raised USD 10 million in Series A funding. Federal funding also helps local and state laboratories increase their capacity and allows them to keep up with increasing demand. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of the Wave platform and novel rapid testing. Molecular diagnostics test menus for infectious diseases cannot afford to be static or superficial due to the diverse nature of infectious diseases and the building resistance of causative agents.

Furthermore, local presence of key players such as Promega Corporation and Thermo Fisher Scientific, which offer cost-effective, high-quality, & a wide range of enzymes to be used in diagnosis, is driving the U.S. market. These companies offer enzymes that can be used in biosensors, diabetes meters, point-of-care devices, and in vitro diagnosis of liver, cardiovascular, renal, and other disorders. Promega introduced a novel enzyme variant in September 2024 that cuts stutter in forensic DNA analysis, highlighting innovation in polymerase kits. Meanwhile, qPCR and RT-PCR kits remain strong, supported by PCR system upgrades and high-throughput lab adoption. In addition, in February 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG enzyme-linked immunosorbent assay kit. It detects IgG antibodies to SARS-CoV-2 in human blood serum or plasma.

Key reagents used in diagnostic assays include fluorescent tags, washing buffers, specific antibodies, and protein biomarkers for immunochemistry tests, along with essential chemicals like dNTP and primer mixes for PCR testing. In molecular diagnostics, fluorescent-labeled nucleotides and primers are frequently utilized, particularly by industry leaders such as Abbott, Illumina, Inc., and Roche Diagnostics.

Regulatory approvals for COVID-19-related reagents have also fueled the market. The U.S. FDA granted 510(k) clearance for the BioFire Respiratory Panel 2.1 in March 2021, enabling the detection of multiple respiratory infections, including COVID-19. Similarly, in April 2020, Ortho Clinical Diagnostics received an Emergency Use Authorization (EUA) for the VITROS Immunodiagnostic Anti-SARS-CoV-2 Total Reagent Pack and Calibrators, which operate on the VITROS diagnostic systems. Such approvals allow healthcare professionals to better manage and prevent COVID-19, even amidst temporary shortages that occurred early in the pandemic. These shortages were eventually mitigated through governmental interventions, restored supply chains, and the launch of alternative products

U.S. Molecular Biology Enzymes, Reagents And Kits Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. molecular biology enzymes, reagents and kits market report based on product, application, and end use

Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Kits & Reagents
  • PCR Kits
  • qPCR Kits
  • RT-PCR Kits
  • Library Preparation Kits
  • Cloning Kits
  • Purification Kits
  • Gene Editing Kits
  • Other Kits
  • Enzymes
  • Polymerases
    • DNA Polymerases
    • High Fidelity DNA Polymerases
    • Pfu DNA Polymerases
    • Phusion DNA Polymerases
    • Hot Start DNA Polymerases
    • Taq DNA Polymerases High Fidelity
    • Others
    • Thermostable DNA Polymerases
    • Standard Taq DNA Polymerases
    • Tth DNA Polymerases
    • Others
    • Strand-displacing DNA Polymerases
    • Bst DNA Polymerases
    • Phi29 DNA Polymerases
    • Others
    • RNA Polymerases
    • T7 RNA Polymerase
    • SP6 RNA Polymerase
    • T3 RNA Polymerase
    • Other RNA Polymerase
  • Reverse Transcriptase (RTs)
    • M-MLV RT
    • AMV RT
    • Thermostable RT
    • Template Switch
    • TGIRT
    • Induro
    • MarathonRT
  • Ligases
    • DNA Ligases
    • T4 DNA Ligases
    • E coli DNA Ligase
    • Taq DNA Ligase
    • Others
    • RNA Ligases
  • Nucleases
    • DNase I
    • RNase A, RNase H
    • Nickases
    • Restriction Nucleases
    • TdTs
  • Endonucleases
    • EndoQ
    • AP Nuclease
  • Kinases
  • Phosphatases
  • CRISPR-associated Enzymes
    • Cas9
    • Cas12a (Cpf1)
    • Cas13
  • Specialty Enzymes
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cloning
  • Sequencing
  • PCR
  • Epigenetics
  • Genotyping
  • RCA/MDA
  • RNA Therapeutics
  • Transcriptomics
  • Proteomics
  • Liquid Biopsy
  • Other Applications
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharma & Biotech
    • Research
    • Therapeutics/Production
  • Academic & Research
  • Hospital & Diagnostics
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Molecular Biology Enzymes, Reagents And Kits Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Molecular Biology Enzymes, Reagents And Kits Market Analysis Tools
    • 3.3.1. Industry Analysis Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Molecular Biology Enzymes, Reagents And Kits Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Molecular Biology Enzymes, Reagents And Kits Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Kits & Reagents
      • 4.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2. PCR Kits
        • 4.4.1.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3. qPCR Kits
        • 4.4.1.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.4. RT-PCR Kits
        • 4.4.1.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.5. Library Preparation Kits
        • 4.4.1.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.6. Cloning Kits
        • 4.4.1.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.7. Purification Kits
        • 4.4.1.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.8. Gene Editing Kits
        • 4.4.1.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.9. Other Kits
        • 4.4.1.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Enzymes
      • 4.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.2. Polymerases
        • 4.4.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.2.2. DNA Polymerases
          • 4.4.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.2. High Fidelity DNA Polymerases
            • 4.4.2.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.2. Pfu DNA Polymerases
      • 4.4.2.2.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.3. Phusion DNA Polymerases
            • 4.4.2.2.2.2.4. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.5. Hot Start DNA Polymerases
            • 4.4.2.2.2.2.6. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.7. Taq DNA Polymerases High Fidelity
          • 4.4.2.2.2.3. Thermostable DNA Polymerases
            • 4.4.2.2.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.2. Standard Taq DNA Polymerases
      • 4.4.2.2.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.3. Tth DNA Polymerases
      • 4.4.2.2.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.4. Others
      • 4.4.2.2.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.4. Strand-displacing DNA Polymerases
          • 4.4.2.2.2.5. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.6. Bst DNA Polymerases
            • 4.4.2.2.2.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.7. Phi29 DNA Polymerases
            • 4.4.2.2.2.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.8. Others
            • 4.4.2.2.2.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.2.3. RNA Polymerases
          • 4.4.2.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.2. T7 RNA Polymerase
            • 4.4.2.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.3. SP6 RNA Polymerase
            • 4.4.2.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.4. T3 RNA Polymerase
            • 4.4.2.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.5. Other RNA Polymerase
            • 4.4.2.2.3.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.3. Reverse Transcriptase (RTs)
        • 4.4.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.2. M-MLV RT
          • 4.4.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.3. AMV RT
          • 4.4.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.4. Thermostable RT
          • 4.4.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.5. Template Switch
          • 4.4.2.3.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.6. TGIRT
          • 4.4.2.3.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.7. Induro
          • 4.4.2.3.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.8. MarathonRT
          • 4.4.2.3.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.4. Ligases
        • 4.4.2.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.4.2. DNA Ligases
          • 4.4.2.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.2. T4 DNA Ligases
          • 4.4.2.4.2.3. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.4. E coli DNA Ligase
          • 4.4.2.4.2.5. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.6. Taq DNA Ligase
          • 4.4.2.4.2.7. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.8. Others
          • 4.4.2.4.2.9. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.4.3. RNA Ligases
          • 4.4.2.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.5. Nucleases
        • 4.4.2.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.2. DNase I
          • 4.4.2.5.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.3. RNase A, RNase H
          • 4.4.2.5.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.4. Nickases
          • 4.4.2.5.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.5. Restriction Nucleases
          • 4.4.2.5.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.6. TdTs
          • 4.4.2.5.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.6. Endonucleases
        • 4.4.2.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.6.2. EndoQ
          • 4.4.2.6.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.6.3. AP Nuclease
          • 4.4.2.6.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.7. Kinases
        • 4.4.2.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.8. Phosphatases
        • 4.4.2.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.9. CRISPR-associated Enzymes
        • 4.4.2.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.2. Cas9
          • 4.4.2.9.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.3. Cas12a (Cpf1)
          • 4.4.2.9.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.4. Cas13
          • 4.4.2.9.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.10. Specialty Enzymes
        • 4.4.2.10.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.11. Others
        • 4.4.2.11.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Molecular Biology Enzymes, Reagents And Kits Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Molecular Biology Enzymes, Reagents And Kits Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Cloning
      • 5.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Sequencing
      • 5.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. PCR
      • 5.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. Epigenetics
      • 5.4.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.5. Genotyping
      • 5.4.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.6. RCA/MDA
      • 5.4.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.7. RNA Therapeutics
      • 5.4.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.8. Transcriptomics
      • 5.4.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.9. Proteomics
      • 5.4.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.10. Liquid Biopsy
      • 5.4.10.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.11. Other Applications
      • 5.4.11.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Molecular Biology Enzymes, Reagents And Kits Market: End use Estimates & Trend Analysis

  • 6.1. End use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Molecular Biology Enzymes, Reagents And Kits Market by End use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Pharma & Biotech
      • 6.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Academic & Research
      • 6.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Hospital & Diagnostics
      • 6.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. Other
      • 6.4.4.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Illumina, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/Strategic Initiatives
    • 7.4.2. Thermo Fisher Scientific, Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/Strategic Initiatives
    • 7.4.3. Agilent Technologies, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/Strategic Initiatives
    • 7.4.4. QIAGEN
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/Strategic Initiatives
    • 7.4.5. Promega Corporation
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/Strategic Initiatives
    • 7.4.6. New England Biolabs
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/Strategic Initiatives
    • 7.4.7. Merck KGaA
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/Strategic Initiatives
    • 7.4.8. F. Hoffmann-La Roche Ltd.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/Strategic Initiatives
    • 7.4.9. Bio-Rad Laboratories, Inc.
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/Strategic Initiatives
    • 7.4.10. Takara Bio, Inc.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/Strategic Initiatives
    • 7.4.11. LGC Limited
      • 7.4.11.1. Participant's Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Recent Developments/Strategic Initiatives